Title: A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors.
Journal: Investigational new drugs 20120201
Title: Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Journal: Cancer chemotherapy and pharmacology 20111201
Title: The debut of a rational treatment for an inherited neuropathy?
Journal: The Journal of clinical investigation 20111201
Title: Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
Journal: The Journal of clinical investigation 20111201
Title: Diastereoselective synthesis and bioactivity of long-chain anti-2-amino-3-alkanols.
Journal: European journal of medicinal chemistry 20111101
Title: Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.
Journal: Chemical reviews 20111012
Title: Aziridines from intramolecular alkene aziridination of sulfamates: reactivity toward carbon nucleophiles. application to the synthesis of spisulosine and its fluoro analogue.
Journal: The Journal of organic chemistry 20110916
Title: Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I.
Journal: Human mutation 20110601
Title: Deoxysphingoid bases as plasma markers in diabetes mellitus.
Journal: Lipids in health and disease 20100101
Title: Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Journal: Molecular cancer therapeutics 20090601
Title: Biodiversity of sphingoid bases ('sphingosines') and related amino alcohols.
Journal: Journal of lipid research 20080801
Title: Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.
Journal: European journal of pharmacology 20080428
Title: Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.
Journal: Die Pharmazie 20060101
Title: Kahalalide F and ES285: potent anticancer agents from marine molluscs.
Journal: Progress in molecular and subcellular biology 20060101
Title: Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
Journal: PDA journal of pharmaceutical science and technology 20050101
Title: Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.
Journal: Journal of chromatography. A 20031212
Title: Efficient synthesis of enantiomerically pure 2-acylaziridines: Facile syntheses of N-Boc-safingol, N-Boc-D-erythro-sphinganine, and N-Boc-spisulosine from a common intermediate.
Journal: The Journal of organic chemistry 20031003
Title: Phenylisothiocyanate and dansyl chloride precolumn derivatizations for the high-performance liquid chromatography analysis of the antitumoral agent ES-285 in dog plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705
Title: Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.
Journal: Journal of mass spectrometry : JMS 20030501
